AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Promising results with oral Lp(a) inhibitor in phase 2 trial
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
Recommended
Details
Presenters
Overview
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring
1.00 credits
<p>Bridging Distances in PAH: Bringing Best Practices to the People Through Telementoring</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
MinuteCE®
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
1.00 credits
<p>Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time</p>
MinuteCE®
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA</p>
CME/CE Broadcast Replay
Pulmonary Hypertension Management: Practice Trends and Updates
1.00 credits
<p>Pulmonary Hypertension Management: Practice Trends and Updates</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
NeuroFrontiers
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms
<p>Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?